Stimwave has raised $50 million to support commercialization of its neuromodulation pain therapies. The financing equips Stimwave to push ahead with its previously disclosed plans to make its devices available across the U.S.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.